Summary
Antineoplastic effects of interferons (IFNs) on brain tumors have often been reported in the literature, however, so far as we know, there are no reports of the study on the antineoplastic effect of IFNs (α, β, and γ) labelled with fluorescein isothiocyanate (FITC) using flow cytometry (FCM). Three established glioma cell lines and 11 cultured cells of brain tumor from surgical specimens were exposed to IFN-α, β, and γ at the concentrations of 102–105 IU/ml for 24 h, respectively. Using FCM, the viability of the cells was evaluated with fluorescein diacetate stain and the cell cycle was analyzed from the DNA-histogram with propidium iodide stain. Furthermore, FITC-labelled IFN-α, β and γ were also contacted with each cell to calculate respective positive cells. The viability decreased about 60% on day 1 and day 3, indicating the effect of IFN-α and β on U373MG cells and on some cultured glioma cells from surgical materials, whereas, IFN-γ had no effects. Antineoplastic effect of each IFN well correlated with FITC-positive rates, demonstrating S phase block in the cell cycle. IFN-γ had no antineoplastic effects, whereas IFN-α and β showed antineoplastic effects, which fact suggested that IFN-γ receptor be different from those of IFN-α and β. The method of FITC-labelling for IFNs with the aid of FCM has the advantages as follows: 1) Antineoplasticity of IFN can be simply evaluated with FCM; 2) It is easy to analyze the action mechanism of IFN; 3) Information on the receptor is obtainable; and 4) Sensitivity can be evaluated prior to administration of IFN, suggesting possibilities of clinical application of this method.
Similar content being viewed by others
References
Gresser I, Bourali C: Antitumor effects of interferon preparations in mice. J Natl Cancer Inst 45: 365–376, 1970
Gresser I, Bourali-Maury C: Inhibition by interferon preparations of a solid malignant tumor and pulmonary metastases in mice. Nature New Biol 236: 78–79, 1972
Ishida N, Fujii T: Antitumor action of interferon. Protein, Nucleic Acid, Enzyme 25: 236–259, 1981
Nagai M, Arai N: Interferon therapy for malignant brain tumors—Present and future. Neurol Surg 10: 463–476, 1982
Thompson MR, Zhang Z, Fournier A, Tan YH: Characterization of human β-interferon-binding sites on human cells. J Biol Chem 260: 563–567, 1985
Kawamoto K, Kawakami K, Kawamura Y, Matsumura H, Ohyama A: New sensitivity test using flow cytometry. J Neuro-Oncol 6: 361–370, 1988
Wada Y, Kawamoto K, Oka S, Yamashita T, Kumazawa T, Kawamoto T: Clinical evaluation for the mechanism of cisplatin with bromodeoxyuridine by flow cytometry and clinico-histological study. Life Sci 44: 259–264, 1989
Kawamoto K, Herz F, Wolley RC, Hirano A, Kajikawa H, Koss LG: Flow cytometric analysis of the DNA distribution in human brain tumors. Acta Neuropath 46: 39–44, 1979
Kawamoto K, Numa Y, Fujiwara H, Ohuchi M, Matsumura H: Flow cytometric study on cell kinetics of brain tumours and their cultured cells. Acta Neurochir (Wien) 97: 150–157, 1989
Fujiwara H, Kawamoto K, Oka N, Kawakami K, Shoda Y, Matsumura H: Basic study on the stain of FITC-labelled monoclonal antibody. Proc Kansai FCM Society 2: 25–30, 1985
Fleischmann WR Jr: Potentiatin of the direct anticellular activity of mouse interferons: Mutual synergism and interferon concentration dependence. Cancer Res 42: 869–875, 1982
Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976–1981, 1983
Korosue K, Tamaki N, Matsumoto S, Takeshita I, Fukui M: Interferon-modification of the in vitro radiation response in cultured human KNS-42 cells. Neurol Med Chir (Tokyo) 24: 233–239, 1984
Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, Kishida T, Imanishi J, Amagai T: Local administration of interferon for malignant brain tumors. Cancer Treat Rep 67: 833–835, 1983
Ueda H. Hirakawa K, Suzuki K, Nakagawa Y, Ibayashi N, Kishida T: Interferon therapy for brain tumor patients. Neurol Surg 10: 149–154, 1982
Fleischmann WR Jr, Newton RC, Fleischmann RC, Colburn NH, Byrsk MM: Discrimination between nonmalignant and malignant cells by combination of IFN-γ and IFN-α/β. J Biol Response Mod 3: 397–405, 1984
Kimoto Y, Taji Y, Origasa H, Usukane M, Fujita M, Taguchi T: Antineoplastic effects by a combination with various interferons. Cancer Chemother 13: 302–307, 1986
Wakabayashi T, Yoshida J, Kobayashi T, Kageyama N, Kanzaki M: Effects of interferon on malignant brain tumors. Cancer Chemother 9: 1400–1406, 1982
Blalock JE, Georgiades JA, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblast of leukocyte interferon. Cell Immunol 47: 390–394, 1980
Tyring S, Klimpel GR, Fleischmann WR Jr, Baron S: Direct cytolysis by partially-purified preparations of immune interferon. Int J Cancer 30: 59–64, 1982
Rosenblum MG, Yung WKA, Kelleher PJ, Ruzicka F, Steck PA, Borden EC: Growth inhibitory effects of interferon-β but not interferon-α on human cells: Correlation of receptor binding, 2′, 5′-oligoadenylate synthetase and protein kinase activity. J Interf Res 10: 141–151, 1990
Helseth E, Torp S, Dalen A, Unsgaard G: Effects of interferon-gamma and tumor necrosis factor-alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastasis. APMIS 97: 569–574, 1989
Branca AA, Baglioni C: Evidence that Type I and II interferons have different receptors. Nature 294: 768–770, 1981
Sokawa Y: XI. Interferon (IFN). Part 2. Med Immunol 10: 393–396, 1985
Yonehara S, Yonehara-Takahashi M, Ishii A: Binding of human interferon α to cells of different sensitivities. Studies with internally radiolabeled interferon retaining full biological activity. J Viorol 45: 1168–1171, 1983
Creasey AA, Bartholomew JC, Merigan TC: Role of G0-G1 arrest in inhibition of tumor cell growth by interferon. Proc Natl Acad Sci 77: 1471–1475, 1980
Fuse A, Kuwata T: Inhibition of DNA synthesis of synchronized RSa cells by human leukocyte interferon. J Natl Cancer Inst 58: 891–896, 1977
Shidara N, Takakura K, Sano K: Interferon and its implication for malignant brain tumor. Neurol Surg7: 645–652, 1979
Matarese GP, Rossi GB: Effect of interferon on growth and division cycle of friend erythroleukemic murine cells in vitro. J Cell Biol 75: 344–354, 1977
Genka S, Shidara N, Tsujita Y, Kosuagi Y, Takakura K: Effect of interferon-β on the cell cycle of human glioma cell line U-251 MG: flow cytometric two-dimensional (BrdU/DNA) analysis. J Neuro-Oncol 6: 299–307, 1988
Kato K, Yoshida J, Kageyama N: Effectiveness of combination therapy of IFN and ACNU for malignant brain tumors. — Clinical effect of local administration of HuIFN-β. Antibiotics Chemother 2: 1812–1816, 1986
Yoshida J, Wakabayashi T, Kato K, Enomoto K, Kito A, Kageyama N: Therapeutic results of combination therapy of IFN-β, ACNU and radiation (IAR). Cancer Chemother 13: 520–524, 1986
Nakamura O, Maruo K, Ueyama Y, Nomura K, Takakura K: Interaction of human fibroblast interferon with chemotherapeutic agents and radiation against human gliomas in nude mice. Neurol Med Chir (Tokyo) 26: 671–676, 1986
Kondo H, Tanaka N, Naramoto Y, Orita K: Effects of combination with rHUIFN-α, β and γ and their effects on cell cycle. Cancer Chemother 14: 1234–1239, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Numa, Y., Kawamoto, K. & Sakai, N. Flow cytometric analysis of antineoplastic effects of interferon-α, β and γ labelled with fluorescein isothiocyanate on cultured brain tumors. J Neuro-Oncol 11, 225–234 (1991). https://doi.org/10.1007/BF00165530
Issue Date:
DOI: https://doi.org/10.1007/BF00165530